Viragen says cancer journal to report that Multiferon following dacarbazine shows significant advantage

By Elaine Rigoli

Tampa, Fla., March 27 - Viragen, Inc. and its majority-owned subsidiary, Viragen International Inc., announced that Acta Oncologica, a leading journal in clinical oncology, has accepted to publish an article profiling Multiferon (multi-subtype, natural human alpha interferon) in the adjuvant treatment of high-risk (stages 2b-3) malignant melanoma.

The article will report on the use of Multiferon following dacarbazine in a clinical trial that demonstrated a statistically significant advantage over untreated controls in terms of distant-metastases-free survival and overall survival, according to a news release.

It is expected to be published this summer, the release said.

Plantation, Fla.-based Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.